Want to see TARA full AI Analyst Report?
TARA Stock Chart & Stats
$3.91
$0.02(0.50%)
At close: 4:00 PM EDT
$3.91
$0.02(0.50%)
Day’s Range― - ―
52-Week Range$2.30 - $7.82
Previous Close$4.11
Volume533.55K
Average Volume (3M)1.45M
Market Cap
$147.74M
Enterprise Value$93.30M
Total Cash (Recent Filing)$17.08M
Total Debt (Recent Filing)$2.75M
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Oct 29, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.36
Shares Outstanding59,095,490
10 Day Avg. Volume970,732
30 Day Avg. Volume1,445,205
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.16
Price to Sales (P/S)0.00
P/FCF Ratio-4.04
Enterprise Value/Market Cap0.63
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.04K
Enterprise Value/Ebitda-1.34
Forecast
1Y Price Target
$24.00Price Target Upside513.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.32
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low leverage reduces the burden of mandatory debt payments and preserves financial flexibility during clinical development. This gives Protara more room to allocate capital toward research programs and manage funding decisions without being heavily constrained by debt obligations.
Unmet-Medical-Need FocusTargeting cancer and rare diseases with significant unmet medical need can support a durable strategic position if development succeeds, because these markets may value meaningful therapeutic advances highly. The focus also aligns research resources with areas where treatment gaps remain substantial.
Multi-Indication Development ProgramStudying TARA-002 across oncology and lymphatic malformations gives the lead program more than one potential clinical application. Progress in either area could broaden the company’s opportunity set, while development across distinct indications may support future commercial optionality.
Bears Say
No Commercial RevenueThe absence of revenue means Protara has not yet demonstrated commercial product demand or an operating revenue base. Until a program reaches approval and sales, the business remains dependent on clinical progress and financing rather than internally generated commercial income.
Widening Net LossesLosses are increasing rather than narrowing, indicating that current spending has not yet translated into improving operating leverage. Persistent and widening deficits can extend the period before profitability and require continued capital allocation while development programs remain unfinished.
Increasing Cash BurnNegative free cash flow in every period, combined with a larger TTM outflow, shows that operations consume substantial cash while the company is still pre-commercial. Continued burn increases reliance on external funding and can limit the resources available for advancing multiple programs.
Protara Therapeutics News
TARA FAQ
What was Protara Therapeutics’s price range in the past 12 months?
Protara Therapeutics lowest stock price was $2.29 and its highest was $7.82 in the past 12 months.
What is Protara Therapeutics’s market cap?
Protara Therapeutics’s market cap is $147.74M.
When is Protara Therapeutics’s upcoming earnings report date?
Protara Therapeutics’s upcoming earnings report date is Oct 29, 2026 which is in 7 days.
How were Protara Therapeutics’s earnings last quarter?
Protara Therapeutics released its earnings results on Aug 11, 2026. The company reported -$0.36 earnings per share for the quarter, missing the consensus estimate of -$0.326 by -$0.034.
Is Protara Therapeutics overvalued?
According to Wall Street analysts Protara Therapeutics’s price is currently Undervalued.
Does Protara Therapeutics pay dividends?
Protara Therapeutics does not currently pay dividends.
What is Protara Therapeutics’s EPS estimate?
Protara Therapeutics’s EPS estimate is -0.37.
How many shares outstanding does Protara Therapeutics have?
Protara Therapeutics has 59,095,490 shares outstanding.
What happened to Protara Therapeutics’s price movement after its last earnings report?
Protara Therapeutics reported an EPS of -$0.36 in its last earnings report, missing expectations of -$0.326. Following the earnings report the stock price went down -4.866%.
Which hedge fund is a major shareholder of Protara Therapeutics?
Currently, no hedge funds are holding shares in TARA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Protara Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.00 (513.81% Upside)
$24.00 (513.81% Upside)
Blogger Sentiment
Bullish
TARA Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 118.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.70%
12-Months-Change
Fundamentals
Return on Equity
-41.72%
Trailing 12-Months
Asset Growth
12.21%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Protara Therapeutics
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.
TARA Stock 12 Month Forecast
Average Price Target
$24.00
▲(513.81% Upside)
Technical Analysis
Minerva Neurosciences
―
Anavex Life Sciences
―
AC Immune SA
―
ProMIS Neurosciences
―
NRX Pharmaceuticals
―
Ownership Overview
2.84% Insiders
6.69% Mutual Funds
<0.01% Other Institutional Investors
80.84% Public Companies and
Individual Investors